STAAR Surgical Co.

As of February 11, 2025, STAAR Surgical Co. is considered a risky investment due to its overvaluation and poor performance metrics, including a Price to Book Value of 2.53, an EV to Sales ratio of 2.39, a ROCE of -51.79%, and a 1-year return of -13.48% compared to the S&P 500's 17.14%.

As of October 1, 2023, there is insufficient technical data for STAAR Surgical Co. to determine if it is bullish or bearish.

As of February 11, 2025, STAAR Surgical Co. is considered risky and overvalued, with key financial metrics indicating poor performance, including a Price to Book Value of 2.53, an EV to Sales ratio of 2.39, and a year-to-date return of -31.33%, compared to the S&P 500's gain of 2.44%.

As of March 2022, the management team of STAAR Surgical Co. includes Independent Chairman Louis Silverman, President and CEO Caren Mason, Directors Thomas Frinzi, Gilbert Kliman, Stephen Farrell, and John Moore. They oversee the company's strategic direction and operations.

STAAR Surgical Co. designs and manufactures implantable lenses for the eye, operating in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $43 million and a net loss of $54 million, with a market cap of $823.62 million.

As of Jun 18, STAAR Surgical Co. has a market capitalization of 823.62 million, with net sales of 279.13 million and a net profit of -71.08 million over the last four quarters. Shareholder's funds are 397.33 million, and total assets amount to 509.52 million.